تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
11.045 US$
−0.165 US$ · -1.47%
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
جلسة التداول العادية
11.045 US$
−0.165 US$ · -1.47%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
نطاق اليوم
السعر الحالي 11.045 US$
نطاق 52 أسبوعًا
السعر الحالي 11.045 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
47
قيمة عادلة
المشاعر
55
مختلط
المخاطر
59
مخاطر أعلى من المعتاد
الزخم
36
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
نطاق اليوم
السعر الحالي 11.045 US$
نطاق 52 أسبوعًا
السعر الحالي 11.045 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
20.33 US$
ارتفاع محتمل بنسبة 84.07%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI6.6 مليون0.00%2.3 ترليون USD0.03%379.69 US$-0.35%
iShares Russell 2000 ETFIWM5.3 مليون0.01%78.56 مليار USD0.19%275.78 US$-0.69%
Vanguard Extended Market ETFVXF2.58 مليون0.00%95.4 مليار USD0.05%231.96 US$-0.66%
iShares Russell 2000 Value ETFIWN1.95 مليون0.01%13.92 مليار USD0.24%209.07 US$-0.45%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV1.79 مليون0.01%26.69 مليار USD0.33%37.705 US$-0.24%
iShares Biotechnology ETFIBB1.54 مليون0.01%10.4 مليار USD0.44%199.42 US$-1.93%
iShares U.S. Small-Cap Equity Factor ETFSMLF1.19 مليون0.03%4.16 مليار USD0.15%84.195 US$-0.51%
EA Bridgeway Omni Small-Cap Value ETFBSVO1.19 مليون0.05%2.37 مليار USD0.45%28.27 US$-0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Biotechnology ETFIBBiShares U.S. Small-Cap Equity Factor ETFSMLFEA Bridgeway Omni Small-Cap Value ETFBSVOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
